Antiviral Drugs Market Projected to Hit $125.26 Billion by 2035

  • Global antiviral drugs market valued at $77.93 billion in 2025, projected to reach $125.26 billion by 2035, with a CAGR of 4.86%.
  • North America held the largest regional share at 47.0% in 2025, while Asia Pacific is expected to record the fastest growth at 6.08% annually.
  • HIV medicines represent 58.0% of indication revenue, with combination therapy comprising 62.0% of revenue.
  • Key players include Gilead Sciences, GSK / ViiV Healthcare, Merck & Co., Pfizer, Shionogi, Cipla, Aurobindo Pharma, Dr. Reddy's Laboratories, and Sun Pharmaceutical.

The antiviral drugs market is driven by the continuing need for HIV treatment, chronic hepatitis management, and emerging respiratory indications. The shift toward long-acting HIV prevention and more convenient treatment combinations is reshaping the market landscape. North America's dominant share and Asia Pacific's rapid growth highlight regional opportunities and access constraints that affect revenue.

Regulatory Approvals
The pace at which new long-acting HIV prevention and streamlined regimens gain regulatory approvals will shape market dynamics.
Generic Competition
Whether patent expiries and tendering will accelerate generic competition in mature HIV and hepatitis medicines.
Regional Growth
How the Asia Pacific region's 6.08% modeled CAGR will impact global market shares and revenue distribution.